Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
HB-adMSC Allogeneic by Hope Biosciences for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
HB-adMSC Allogeneic is under clinical development by Hope Biosciences and currently in Phase II for Post-Acute Sequelae of COVID 2019...
Data Insights
HB-adMSC Allogeneic by Hope Biosciences for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
HB-adMSC Allogeneic is under clinical development by Hope Biosciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According...